GLP-1 receptor agonists have created the largest new drug market in pharmaceutical history. Novo Nordisk's Wegovy and Ozempic generated over $20 billion in combined 2025 revenue, with Wegovy establishing obesity as a fully reimbursed chronic disease indication. Eli Lilly's tirzepatide (Zepbound/Mounjaro) — a dual GIP/GLP-1 agonist — has demonstrated superior weight loss efficacy and is the fastest-growing drug in pharmaceutical history. The competitive landscape is intensifying — Amgen's MariTide, Pfizer's danuglipron, and dozens of next-generation oral and injectable GLP-1 agents are in clinical development, threatening Novo Nordisk's dominant market position.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• GLP-1 Market Dynamics
• Wegovy and Ozempic Commercial Performance
• Tirzepatide Competitive Threat
• Next-Generation GLP-1 Pipeline
• Oral GLP-1 Development
• Renal and Cardiovascular GLP-1 Indications
• Manufacturing Capacity Race
• Biosimilar GLP-1 Outlook
Table of Contents
1. Executive Summary
2. Market Overview
3. GLP-1 Market Dynamics
4. Wegovy and Ozempic Commercial Performance
5. Tirzepatide Competitive Threat
6. Next-Generation GLP-1 Pipeline
7. Oral GLP-1 Development
8. Renal and Cardiovascular GLP-1 Indications
9. Manufacturing Capacity Race
10. Biosimilar GLP-1 Outlook
11. Competitive Landscape
12. Regional Market Analysis
13. Strategic Conclusions and Recommendations
14. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Pipeline Assessment 2025
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Novo Nordisk
Eli Lilly
Sanofi
AstraZeneca
Pfizer
Roche
Viking Therapeutics
Structure Therapeutics
